Overview of the current role of stereotactic body radiotherapy in the treatment of unfavorable intermediate- and high-risk prostate cancer

on behalf of the ISRS Working Group on Prostate Radiosurgery

Overview of the current role of stereotactic body radiotherapy in the treatment of unfavorable intermediate- and high-risk prostate cancer

on behalf of the ISRS Working Group on Prostate Radiosurgery

University of Latvia
University of Toronto
Sigulda Hospital Centre of Stereotactic Radiosurgery
Maria Sklodowska-Curie Institute of Oncology

Research output: Contribution to journal › Article › peer-review

Abstract

Stereotactic body radiotherapy (SBRT) is well accepted for low- and intermediate-favorable risk prostate cancer. Available evidence about the application of SBRT in unfavorable- and high-risk prostate cancer is less solid. During last year’s multiple variations in treatment, techniques have been reported making comparisons more complicated. This review’s objective is to review current evidence in application of SBRT in intermediate unfavourable and high-risk prostate cancer and to outline variations in SBRT treatment techniques and relevant results.

Original language	English
Pages (from-to)	95-103
Journal	Journal of Radiosurgery and SBRT
Volume	8
Issue number	2
Publication status	Published - 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

OECD Field of Science

3. Medical and Health Sciences

Keywords

high-risk prostate cancer
Intermediate unfavorable
SBRT
stereotactic body radiotherapy

Cite this

@article{b241ff1d7317420ebcd810433b450566,

title = "Overview of the current role of stereotactic body radiotherapy in the treatment of unfavorable intermediate- and high-risk prostate cancer",

abstract = "Stereotactic body radiotherapy (SBRT) is well accepted for low- and intermediate-favorable risk prostate cancer. Available evidence about the application of SBRT in unfavorable- and high-risk prostate cancer is less solid. During last year{\textquoteright}s multiple variations in treatment, techniques have been reported making comparisons more complicated. This review{\textquoteright}s objective is to review current evidence in application of SBRT in intermediate unfavourable and high-risk prostate cancer and to outline variations in SBRT treatment techniques and relevant results.",

keywords = "high-risk prostate cancer, Intermediate unfavorable, SBRT, stereotactic body radiotherapy",

author = "\{on behalf of the ISRS Working Group on Prostate Radiosurgery\} and Maris Mezeckis and Danny Vesprini and Vladyslav Buryk and Leszek Miszczyk and Egils Vjaters",

note = "Publisher Copyright: {\textcopyright} 2022 Old City Publishing, Inc.",

year = "2022",

language = "English",

volume = "8",

pages = "95--103",

journal = "Journal of Radiosurgery and SBRT",

issn = "2156-4639",

publisher = "Old City Publishing",

number = "2",

}

TY - JOUR

T1 - Overview of the current role of stereotactic body radiotherapy in the treatment of unfavorable intermediate- and high-risk prostate cancer

AU - on behalf of the ISRS Working Group on Prostate Radiosurgery

AU - Mezeckis, Maris

AU - Vesprini, Danny

AU - Buryk, Vladyslav

AU - Miszczyk, Leszek

AU - Vjaters, Egils

PY - 2022

Y1 - 2022

N2 - Stereotactic body radiotherapy (SBRT) is well accepted for low- and intermediate-favorable risk prostate cancer. Available evidence about the application of SBRT in unfavorable- and high-risk prostate cancer is less solid. During last year’s multiple variations in treatment, techniques have been reported making comparisons more complicated. This review’s objective is to review current evidence in application of SBRT in intermediate unfavourable and high-risk prostate cancer and to outline variations in SBRT treatment techniques and relevant results.

AB - Stereotactic body radiotherapy (SBRT) is well accepted for low- and intermediate-favorable risk prostate cancer. Available evidence about the application of SBRT in unfavorable- and high-risk prostate cancer is less solid. During last year’s multiple variations in treatment, techniques have been reported making comparisons more complicated. This review’s objective is to review current evidence in application of SBRT in intermediate unfavourable and high-risk prostate cancer and to outline variations in SBRT treatment techniques and relevant results.

KW - high-risk prostate cancer

KW - Intermediate unfavorable

KW - SBRT

KW - stereotactic body radiotherapy

UR - https://www.oldcitypublishing.com/journals/jrsbrt-home/jrsbrt-issue-contents/journal-of-radiosurgery-sbrt-volume-8-number-2-2022/journal-of-radiosurgery-sbrt-8-2-p-95-103/

UR - https://www.scopus.com/pages/publications/85188778455

M3 - Article

SN - 2156-4639

VL - 8

SP - 95

EP - 103

JO - Journal of Radiosurgery and SBRT

JF - Journal of Radiosurgery and SBRT

IS - 2

ER -

Overview of the current role of stereotactic body radiotherapy in the treatment of unfavorable intermediate- and high-risk prostate cancer

Abstract

UN SDGs

OECD Field of Science

Keywords

Other files and links

Fingerprint

Cite this